About INT
Integrated Nanotherapeutics (INT) is a preclinical-stage company pioneering antigen-specific immune tolerance therapies using lipid nanoparticles (LNPs).
Our proprietary drug delivery platform can deliver any type of drug modality in LNPs, either alone or in combination, with tunable cargo release profiles. The unique ability to co-deliver mRNA and small molecules enables a plug-and-play platform to treat autoimmunity at its root cause.
People
Integrated Nanotherapeutics is founded by a team of world-class scientists with multi-disciplinary skills in basic science, preclinical research, drug development, and commercialization of therapeutics. We have collectively over 100 years of experience in lipid nanoparticle (LNP) science and drug development. Our founding team and scientists have contributed to 5 approved LNP drugs (out of a total of 14). These include Abelcet®, Myocet®, Marqibo®, Onpattro® and Comirnaty®.
Mission
We are developing first-in-class immune tolerance therapies that address autoimmune diseases at their root cause.
Our mission is to unlock the full therapeutic potential of diverse compounds through innovative, precision-engineered drug delivery systems, creating safe and effective treatments that transform patient lives.
Technologies
Immune Tolerance Platform
Our modular immune tolerance platform enables the development of therapies to treat many immune diseases including type 1 diabetes, MS and allergy.
Drug Delivery Platform
Our versatile drug delivery platform allows the incorporation of virtually any small molecule and/or biologic into lipid nanoparticles (LNPs).
Partnering
We welcome partnering opportunities with academic and industry groups. INT has developed a broad IP portfolio focused on the use of LNPs for delivery of small molecules, and macromolecules such as nucleic acids and peptides.
We have a solid track record of successfully working with local and international partners to advance their preclinical assets. With deep understanding of drug development process from discovery to regulatory approval, we have formed long-lasting relationships with our partners.
Email us at bd@integratedntx.com to learn more about how our team and technologies can help you reach your drug development goals.